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Significance of the study
What is already known about this subject?
 ► Inverted papilloma of the conjunctiva is an exceed-
ingly rare tumour.
 ► Due to the rarity, the biology and malignant potential 
of these tumours are uncertain.
What are the new findings?
 ► Here we describe the clinical and histopathological 
features of the tumours in the largest published 
series to date and have furthermore found an as-
sociation between the tumour and high-risk human 
papillomavirus.
How might these results change the focus of 
research or clinical practice?
 ► The finding of high-risk human papillomavirus in our 
series, and thereby a risk of malignant transforma-
tion, underlines the necessity of complete excision 
and careful observation of these tumours.
AbsTrACT
Objective The purpose of the present study is to describe 
the clinical and histopathological features of conjunctival 
inverted papilloma, to analyse for the presence of human 
papillomavirus (HPV), and to determine if HPV infection is 
associated with this type of tumour and its inverted growth 
pattern.
Methods and Analysis Cases of conjunctival inverted 
papillomas were retrieved from the archives of the 
Department of Pathology, Rigshospitalet, Denmark. Patient 
records and pathology reports were reviewed. Formalin-
fixed and paraffin-embedded tissue was analysed for 
the presence of HPV by immunohistochemistry, in situ 
hybridisation (ISH), PCR and HPV typed by sequencing.
results A total of four cases were retrieved. The age 
at diagnosis ranged from 41 to 77 years, with an equal 
sex distribution. All lesions were localised to the bulbar 
conjunctiva and two of the cases were pigmented. 
Histopathological examination did not reveal areas 
of dysplasia. All lesions were p16-positive and p53-
positive by immunohistochemistry. High-risk HPV 58 was 
demonstrated in one lesion by ISH and PCR.
Conclusion Here we present four cases of conjunctival 
inverted papilloma, which is an exceedingly rare tumour 
with only 11 previously reported cases in the literature. 
Both clinically and histopathologically, the tumours show 
distinct features compared with exophytic conjunctival 
papillomas. Furthermore, this is the first description of 
high-risk HPV 58 in a conjunctival tumour. The biological 
behaviour of the tumour is uncertain due to its rareness. 
However, a complete removal of the lesion and a careful 
observation are recommended. The finding of HPV 58 
underlines the necessity of this precaution.
InTrOduCTIOn
Papillomas are benign epithelial lesions of 
the mucous membranes. Conjunctival papil-
lomas are histopathologically divided into 
exophytic and inverted papillomas. The 
inverted papilloma consists of folds of papil-
lomatous epithelium that invaginate into the 
underlying stroma, rather than growing in a 
purely exophytic fashion that is characteristic 
of the far more common exophytic squamous 
papilloma.1 In the neighbouring regions, 
inverted papilloma usually originates in the 
nasal cavity and paranasal sinuses.2
Inverted conjunctival papilloma is 
exceedingly rare. To date, only 11 cases of 
inverted conjunctival papilloma have been 
reported.3–10 Due to its rareness, the aetiology 
and underlying biology are uncertain. Recur-
rence and malignant transformation occurred 
in 2 of the 11 cases described.5 10
Low-risk human papillomavirus (LR-HPV) 
is associated with the occurrence of exophytic 
conjunctival papilloma.11 HPV is a DNA virus 
with a double-stranded DNA genome, and 
variations in the DNA sequence define the 
more than 200 different genotypes,12 typically 
stratified into two groups targeting either the 
mucosal or cutaneous tissue (International 
Agency for Research on Cancer [IARC] 
Monograph, 2012). The IARC has defined 
13 HPV genotypes as carcinogenic to humans 
based on sufficient evidence of carcinoge-
nicity, hereafter referred to as high-risk HPV 
(HR-HPV).
The purposes of the present study are 
to describe the clinical and pathological 
features of conjunctival inverted papillomas, 
and furthermore to determine if HPV is asso-
ciated with this tumour type and its inverted 
growth pattern.
MATerIAls And MeTHOds
sample selection
Cases of inverted conjunctival papillomas 
were retrieved from the archives of the Eye 
Pathology Section, Department of Pathology, 
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Rigshospitalet, which is the centralised, national 
ophthalmic pathology laboratory in Denmark. Histolog-
ical review of the original diagnosis was performed for 
each specimen to confirm the diagnosis. Formalin-fixed 
and paraffin-embedded (FFPE) specimens were collected. 
Clinical and histopathological data including age, sex, 
localisation, duration of symptoms, clinical appearance, 
recurrence, treatment and histopathological features 
were gathered from the referring ophthalmologist and 
from pathology reports.
Immunohistochemistry
P16 immunohistochemistry (IHC) was performed as 
supplement and surrogate marker of HPV infection.13 
P53 IHC was performed as an indicator of ultraviolet-in-
duced tumour growth.14 IHC was performed on a Ventana 
BenchMark ULTRA IHC/ISH Staining Module (Ventana 
Medical Systems, Tucson, Arizona, USA) according to 
the manufacturer’s recommendations. P16 was detected 
by incubating sections with monoclonal mouse antibody 
CINtec p16 clone E6H4, and p53 was detected with 
monoclonal mouse antibody clone DO7 (both Roche 
Diagnostics). Slides were counterstained with haematox-
ylin. The threshold of p16 positivity was >70% positive 
nuclear and cytoplasmic staining with medium to strong 
intensity.13 Marked p53 accumulation of at least 20% 
cell staining has been considered positive, according to 
Nordic Immunohistochemical Quality Control (http://
www. NordiQC. org; Aalborg University Hospital).
In situ hybridisation
In situ hybridisation (ISH) for high-risk HPV DNA 
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 66 was 
performed by Inform HPV III Family 16 Probe (Ventana 
Medical Systems) according to the manufacturer’s guide-
lines using a BenchMark automated slide staining system 
(Ventana Medical Systems). The specimens were dichot-
omously classified as positive or negative.
dnA extraction and detection of type-specific HPV
DNA extraction from FFPE was done using a 10 µm tissue 
section of the archival material. Proteinase K treatment 
and subsequent DNA extraction were performed using 
the QIAamp DNA FFPE extraction kit and the QIAcube 
extraction unit (both Qiagen, Hilden, Germany) in 
concordance with the manufacturer’s specifications.
HPV detection: nested PCR assay
Nested PCR with PGMY 09/11 L1 consensus primers and 
GP5+/GP6+ L1 consensus primers was used to analyse 
the extracted DNA samples as previously described by 
Rusan et al.15 Briefly, PCR reactions with PGMY 09/11 
primers were performed in the first reaction and 
GP5+/GP6+ primers in the second reaction. Samples 
were run in duplicate. HPV plasmids for HPV 6, HPV 
16 and HPV 18 were used as positive controls. Nega-
tive controls consisted of 5 µL of diethyl pyrocarbonate 
(DEPC)-treated H
2
O, instead of template. The RNase P 
housekeeping gene was used to verify that amplifiable 
DNA was present in all DNA extracts (TaqMan RNase P 
detection kit, Applied Biosystems). Positive samples were 
run on a 2% agarose gel, extracted using the QIAquick 
Gel Extraction Kit (Qiagen) and sent for sequencing 
to Eurofins MWG Operon. The positive and negative 
controls used in the PCR reaction were also run on the 
gel, and the positive controls were extracted and sent for 
sequencing. The one positive sample, along with several 
negative samples, was reanalysed to check for consis-
tency.
HPV detection: CLART HPV2 clinical array
The CLART Human Papillomavirus 2 Kit (Genomica, 
Madrid, Spain) is a clinically validated HPV assay that can 
be used on multiple types of sample types. CLART2 is a 
low-density microarray system that individually detects 35 
clinically relevant HPV types (6, 11, 16, 18, 26, 31, 33, 35, 
39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 
68, 70, 71, 72, 73, 81, 82, 83, 84, 85 and 89).15–17 Detection 
of HPV genotypes was achieved by PCR amplification of 
a 465 base pair fragment within the L1 region as previ-
ously described.18 The assay includes a control for the 
presence of genomic DNA (amplification of the human 
cystic fibrosis transmembrane conductance regulator 
[CFTR] gene) and an amplification control (amplifica-
tion of a CFTR plasmid).15 Interpretation of the results 
was performed automatically by a Clinical Array Reader.
resulTs
Four cases of conjunctival inverted papillomas were 
retrieved from our files. Review of the patient journals 
and pathology files revealed a range of age at diagnosis 
from 41 to 77 years, with an equal sex distribution. The 
duration of the symptoms ranged from 1 year to more 
than 20 years. Two of the lesions were clinically mistaken 
for being a nevus due to the pigmented appearance 
(figure 1A). Three of the lesions were localised to the 
medial bulbar conjunctiva and one localised to the lateral 
limbus. All the cases were treated with complete excision 
without adjuvant therapy. Histopathological examination 
showed the invagination of the conjunctival epithelium 
into the stroma (figure 1B,C), and re-examination did 
not disclose any areas of intraepithelial dysplasia or inva-
siveness. None of the lesions recurred or progressed to 
malignancy within the follow-up time (minimum of 4 
years). Clinical and histopathological information is 
listed in table 1.
All tumours were positive in p53 IHC and one tumour 
was positive in p16 IHC (table 2, figure 1D,E).
Two of the four specimens were excluded from PCR 
due to insufficient tissue and DNA. HR-HPV 58 was iden-
tified by both PCR and CLART in one of the two inverted 
conjunctival papillomas available for PCR analysis 
(figure 1F). The same specimen was also positive by DNA 
ISH, whereas the three other tumours were HPV-negative 
using ISH.
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Figure 1 (A) Inverted papilloma of the conjunctiva on the medial bulbar conjunctiva in a 77-year-old woman, clinically 
mistaken for a nevus due to the pigmented appearance (arrows). (B) The epithelium of the inverted conjunctival papilloma 
invaginates into the underlying stroma with no signs of dysplasia (H&E, scale bar=100 µm). (C) A higher magnification of the 
tumour reveals no cellular atypia (H&E, scale bar=20 µm). (D) Nuclear staining of p53, particularly in the basal epithelial layers of 
the tumour (scale bar=50 µm). (E) Diffuse overexpression of p16 with medium intensity in the tumour tissue (scale bar=70 µm). 
(F) The figure shows one HPV-negative and one HPV 58-positive sample. P, positioning control to ensure correct positioning 
of the array in the automated reader; V, visualisation control to ensure correct visualisation levels on the array; IC, internal 
control (spiked rhesus CFTR plasmid, amplicon ≈1200 bp), control for adequate PCR amplification; DNA, control for sample 
adequacy (human CFTR gene detection, amplicon ≈800 bp); HPV 58, specific probe reaction to PCR amplification of HPV 58 
in the sample (amplicon ≈450 bp). bp, base pair; CFTR, cystic fibrosis transmembrane conductance regulator; HPV, human 
papillomavirus.
dIsCussIOn
The previously reported cases of inverted conjunctival 
papillomas have shown a broad variety regarding the clin-
ical appearance, in accordance to our results. Inverted 
papillomas are described as pigmented, partly pigmented 
or completely unpigmented lesions, enlarging over a few 
months to several years and affecting females and males 
equally.3–10 Yet it is worth noticing that pigmentation of 
the papilloma by clinical evaluation has been described 
in 5 out of 15 lesions, in contrast to exophytic papilloma 
where pigmentation is rarely described. In the present 
series, this correlates to the histopathological finding 
of hyperpigmentation of the basal layers of the epithe-
lium. The localisation of the lesions is scattered all over 
conjunctiva, however more frequently reported in the 
nasal part of the conjunctiva, which is seen in 10 out of 
15 reported cases. Ten out of 15 cases were epibulbar. 
Unlike exophytic papillomas which are most often local-
ised inferiorly, a superior location is more common in 
inverted papillomas (table 1). All present cases have 
been treated exclusively by surgical removal. This is 
the case also in previously reported cases, except in 
two cases where adjuvant cryotherapy and neoadjuvant 
local chemotherapy with Mitomycin were applied.8 10 In 
table 3, we have summarised the clinical characteristics 
of inverted conjunctival papillomas compared with the 
exophytic papillomas.
Histopathologically, no lesion has been reported with a 
keratinising epithelium, which was also the finding in the 
present cases. None of the present cases showed cellular 
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Table 2 Results of the HPV analyses
Present case P16 IHC* P53 IHC** In situ hybridisation β-globin PCR
1 Negative Positive Negative Negative NA
2 Negative Positive Negative Positive Negative
3 Positive NA Positive Positive HPV 58-positive
4 Negative Positive Negative Negative NA
* Nuclear and cytoplasmic staining of tumor cells by immunohistochemistry. ** Nuclear staining of tumor cells by immunohistochemistry.
HPV, human papillomavirus; IHC, immunohistochemistry; NA, not available; PCR, polymerase chain reaction.
Table 3 Clinical features of exophytic papilloma versus 
inverted papilloma of the conjunctiva
Inverted 
papilloma3–10
Exophytic 
papilloma20
Age (mean, range) 53.2 years (11–85) 39.6 years (17–84)
Sex Even gender 
distribution
Male 
predominance
Appearance Commonly 
pigmented
Rarely pigmented
Localisation Most often nasal 
and superiorly
Most often nasal, 
inferiorly and at 
the caruncle
Malignancy Described in 2 of 
15 at the time of 
diagnosis
Synchronous 
carcinoma rare
Human 
papillomavirus 
(HPV)
2 of 6 of tested 
lesions HPV-
positive
Strongly 
associated with 
low-risk HPV types
atypia, dysplasia or invasive growth. However, of 11 
previously reported cases in the literature, 2 showed an 
aggressive behaviour.5 10 Both of these conjunctival papil-
lomas had carcinomatous foci at the time of diagnosis, 
and one of them recurred 4 months after primary exci-
sion.5 Studies of the regionally close sinonasal mucosa 
have shown that at least 15% of all cases of sinonasal papil-
lomas have developed synchronously or metachronously 
squamous cell carcinoma,2 and that sinonasal inverted 
papillomas are more often associated with development 
of recurrence, worsening of dysplasia and development 
of malignancy compared with exophytic papillomas.19
All the cases available to p53 IHC (one missing due to 
lack of tumour tissue) were positive. There is a hypothesis 
that p53 overexpression correlates with ultraviolet-in-
duced tumour growth14; however, it is not a specific 
marker, and in concordance with a previous reported 
case of conjunctival inverted papilloma the p53 expres-
sion in our series is lower than the expression frequently 
seen in carcinoma of the conjunctiva.8
In the present study, we have shown HR-HPV 58 in one 
of two investigated conjunctival inverted papillomas avail-
able for PCR analysis. This lesion was also positive by p16 
IHC and HPV-positive by ISH. This is, to our knowledge, 
the first study demonstrating the presence of an HR-HPV 
58 in a conjunctival lesion. A test for the presence of HPV 
has been done in 4 of the 11 reported cases of inverted 
conjunctival papillomas.4 7 8 10 HPV was detected in one 
case, but the viral genotype was in that case not deter-
mined.4
In the more common exophytic conjunctival papil-
loma, there is a strong association to HPV, as HPV has 
been detected in 81%–92% in large case series.11 20 
LR-HPV 6 and 11 are the most common types detected 
in these lesions, in accordance to their benign clinical 
nature. Only rarely, there are reported high-risk subtypes 
16, 33 and 45 in exophytic conjunctival papilloma.11 20–22 
These oncogenic HPV types are more often detected in 
epithelial malignant lesions of the conjunctiva, although 
the aetiological role of the virus in conjunctival squamous 
cell carcinoma remains controversial.
In sinonasal inverted papilloma, LR-HPV 6 and 11 
and HR-HPV 16, 18 and 57 have been demonstrated.23 
However, the detection rate is highly variable, with a 
reported range of 0%–100%.19 24 The possible oncogenic 
role of HPV in the progression of sinonasal inverted 
papillomas has been proposed in many studies.25
Different theories may explain why the presence of 
HPV differs in inverted and exophytic papillomas. First, 
the hyperkeratotic superficial epithelium of exophytic 
papillomas is susceptible for HPV replication because 
reinfection of the papilloma by assembled virions may 
occur. In contrast, inverted papillomas tend to be non-ke-
ratinising, and as superficial epithelium is shed, HPV is 
lost, accounting for the lower detection rate.19 Second, 
HPV assays used for these types of studies are most often 
without defined clinical cut-offs, rendering any analysis 
dependent on the performing laboratory’s ability to run 
high-definition HPV assays. Here, we use a well-charac-
terised, quality-controlled, clinical HPV array assay with 
a WHO Laboratory Network proficiency study-validated 
detection of all 13 HR-HPV genotypes plus HPV 6 and 
11.26 27 Therefore, the inability to detect HPV DNA does 
not necessarily abolish a viral role in the tumour develop-
ment of inverted papillomas.
In conclusion, HR-HPV 58 was identified in one of 
two inverted conjunctival papillomas with a successful 
DNA extraction. To our knowledge, this is the first study 
demonstrating HPV 58 in a conjunctival papilloma. HPV 
58 is characterised as a high-risk HPV due to its onco-
genic potential in other tissue types. Due to the rarity 
of inverted conjunctival papilloma, their biological 
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behaviour is uncertain. However, since HPV 58 has a 
significant oncogenic potential and because of the high 
incidence of recurrence and association to malignancy 
of inverted papilloma in the neighbouring sinonasal 
region, inverted papillomas of the conjunctiva should be 
removed completely and the patients carefully observed. 
Our finding of HR-HPV 58 underlines the necessity of 
this precaution.
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